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Background: Vaccine wastage is one of quality indicators of immunization program and high vaccine wastage will
increase overall costs and impede efforts towards a more efficient and sustainable program. We aimed at esti-
mating of the wastage rates of Measles-Mumps-Rubella (MMR) and pentavalent (diphtheria-tetanus-pertussis-
hepatitis B -Haemophilus influenza type b) vaccines in different vaccine vial sizes.
Study design: Multicentre descriptive study using existing data.
Methods: This study was in three provinces (Hamadan, Kermanshah and Kordestan) of Iran including 131,135
populations with 2,548 under-1years children. Twenty-seven health facilities were selected randomly from nine
districts in three provinces of western part of Iran. Six-months data including vaccination and vaccine stock re-
cords collected from April to September 2017. Finally, number of opened vials and number of target population
vaccinated were collected and data were analysed to estimate the wastage rates in both unopened and opened
vials of both antigens.
Results: The wastage rate for combined MMR 2-dose and 5-dose opened vials for three provinces was
29%(Hamadan 18%, Kermanshah 14% and Kordestan 52%). The wastage rate for combined pentavalent single-
dose and 10-dose vials for three provinces was 17% (in Kordestan33%, 11% Kermanshah 11% and Hamedan 3%).
The total average of pentavalent single-dose and 10-dose vials wastage rate was 5% and varied 13% for urban and
3% for rural areas. The average of discarded unopened vials wastage rate in all facilities for MMR was 3.9% (3.2%
for MMR 2-dose vial and 10.2% for MMR 5-dose vial). This rate was 1.7% for pentavalent total (1.9% for single
dose vial and 0.4% for 10 dose vial).
Conclusion: The vaccine wastage rates in Iran are in line with other countries and lower than the suggested rate
based on WHO policies for multi-dose vials. The wastage rates were different for in provinces, districts and health
facilities. The MMR total wastage rate in rural is higher than those in urban areas. However, the pentavalent total
wastage rate was higher in urban area.1. Introduction
The vaccine wastage rate is one of the critical quality indicators of an
immunization program since vaccines represent a significant proportion
of the program costs and defined as the proportion of doses of opened or
unopened vaccine vials are not used for vaccination [1, 2, 3]. Based on
the World Health Organization (WHO) reports the vaccine wastageadbeigi).
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is an open access article under taround the world is over 50% [4]. The introduction of new and more
expensive vaccines brings additional complexity to vaccine wastage
control. In one hand, a high vaccine wastage will increase overall costs
and impede efforts towards a more efficient and sustainable program [5,
6]. In the other hand, the fear of increasing wastage by opening
multi-dose vials potentially limits access to vaccination services andy 2020
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tional immunization programs [7].
There are two types of vaccine wastage including opened and un-
opened or closed vial wastages [1, 7]. The opened vial wastage is asso-
ciated with the use of multi-dose vials for vaccination. Unopened or
closed vial wastage is related to gaps in stock inventory control and poor
vaccine management practices [8, 9]. Every effort must be made to avoid
wastage in unopened vials. The successful implementation of effective
vaccine management practices will maintain low wastage rates of un-
opened vials [1, 2]. In contrast, opened vial wastage is unavoidable.
Doses discarded with multi-dose vials may be high depending on the vial
size, the compliance with multi-dose vial policy (MDVP), and the size and
frequency of vaccination sessions [8]. Undue pressure on health workers
to reduce wastage may push them to abstain from opening multi-dose
vials when the number of children is insufficient. This can lead to a
low coverage and must be avoided [3, 8].
The Government of Islamic Republic of Iran is investing great efforts
for sustaining the high performance of the national immunization pro-
gram [10, 11] and administrating new vaccines such as pentavalent
(including diphtheria-tetanus-pertussis-hepatitis B-Haemophilus influ-
enza type b) [12]. pentavalent vaccine (adsorbed) as a part of the na-
tional paediatric vaccination schedule in Iran started from 2014 and
administrated for three time in under 1 years old children at 2, 4 and 6
months after birth [12, 13]. Measles-Mumps-Rubella (MMR) vaccination
in Iran started at 2004 and MMR vaccine scheduled two times in chil-
dren. The first dose administrating at 12th and second dose at 18th month
after birth [14].
In Iran where all costs for vaccination are covered by the government
alone, that high wastage increases vaccine demand and inflates vaccine
procurement and supply costs [10, 15]. Reduction of vaccine wastage is a
priority of the Ministry of Health and Medical Education. A special focus
is made on MMR vaccine, as the country is moving towards disease
elimination [16, 17]. Currently, by using a mix of 2 and 5-dose vials of
MMR vaccines, a high and on-time immunization coverage is acquired in
Iran [11, 18]. However, the decision to open the relevant vaccine vial size
at each service delivery point for each session remains at the intuitive
decision of individual healthcare workers [5, 6, 9]. Overall reported
wastage rates remain high globally. In 1992, WHO estimated that the
amount of vaccine wasted (60%) accounted for more vaccine than was
administered. In 1994, after switching to smaller multi-dose vials, vac-
cine wastage rates in some areas were reduced to 45% of vaccine demand
[19]. Selection of the appropriate vial size is a complex decision that
should be supported by an evidence-based rational by a cost-effective
approach to minimize the cost of vaccination [20].
To now, we not found an estimate from vaccine wastage in Iran based
a national survey. The current study aimed to provide an estimation of
vaccine wastage rate, type and place of occurrence for Measles-Mumps-
Rubella (MMR) and pentavalent vaccines.
2. Materials and methods
This multicentre descriptive study using existing data was conducted
in 27 health facilities that selected randomly in nine districts of three
western provinces that including 131,135 populations (2,548 were
under-1 age, 1.94%). The setting provinces were Hamedan including
40,319 people (830 were under-1 age, 2.06%), Kermanshah including
49,724 people (926 were under-1 age, 1.86%) and Kordestan including
41,092 people (792 were under-1 age, 1.93%). Three studied provinces
have same socioeconomic status at west of Iran. The maximum, average
and minimum of the target population (under-1 age group) in all 27 fa-
cilities included in the study were 202, 47 and 2, respectively.
There are 9 regional vaccine stores in Iran. One of the nine was
selected randomly which includes 3 provinces named Kordestan, Ker-
manshah and Hamadan in western part of the country. Then three dis-
tricts were selected from each of the provinces randomly. Two rural
health facilities and one urban health post were again randomly selected2
from the list of all the existing health facilities in the selected districts.
Therefore, the total of selected 27 health facilities in three provinces are
shown in Table 1 and the target population of each facility considered per
annum.
The lasted 6 months and consisted of retrospective data collection
conducted and analysis of vaccine utilization and wastage data was done
at selected sites. This study covers data from April to September 2017.
Data on number and frequency of vaccination sessions collected and data
were analysed to map the number of doses administered per session.
2.1. Data collection
The vaccine stock and vaccination records were collected for each
district and used for analysis. Vaccine stock records was the source in all
vaccine stores and health facilities included in the assessment. The wide
implementation of Web-based Vaccination Supplies Stock Management
(wVSSM) facilitated the collection of stock data. This tool approved by
WHO and UNICEEF for vaccine stock management. Different data were
collected and used to estimate wastage occurring in unopened vials
during the storage including stock at the beginning and the end of month,
number of vaccine doses received per month throughout the project
period, number of vaccine doses discarded due to expiry during the
month, number of vaccine doses discarded due to reaching stages 3 and 4
of vaccine vial monitor (VVM) during the month, number of vaccine
doses discarded due to exposure to freezing temperatures (only for
pentavalent) during the month and number of vaccine doses discarded
due to any other reason different from those listed above during the
month.
Vaccination records were collected data at the service delivery level.
At the health facilities the vaccination records were collected using
documents/forms available (daily vaccination tally sheets, vaccination
registers and any other document available with the relevant informa-
tion). Therefore, data of vaccination records including date and type of
vaccination session conducted (fixed, outreach, mobile), number of
children vaccinated per vaccination session and number of vaccine vials
opened for use, were collected.
2.2. Data analysis
The vaccine utilization and wastage indicators were calculated
including 1. Cumulative wastage rates in opened vials that were calcu-
lated for each service point using the total number of doses of vials
opened and the total vaccinations given. 2. Wastage rates in unopened
vials that was calculated for each storage point as the proportion of total
doses discarded in closed vials over the total doses handled. 3. The
weighted average wastage for urban versus health facilities.
Data collected were analysed to provide an estimation of frequency
and number of children vaccinated in vaccination sessions conducted per
service point, number of vaccine doses used versus vaccine doses
administered, number of vaccine doses received and wasted in unopened
vials during storage and handling, and vaccine wastage rates, both in
unopened vials and in opened vials. Vaccine wastage was defined as 1
minus vaccine usage and the vaccine usage can be defined as the pro-
portion of vaccine issued (including doses used for immunization and all
doses discarded or lost for any reason such as expiry, VVM indication,
cold chain failure, freezing, missing inventory or routine discard of open
vials of vaccine at the end of a session) which is administered [4].
Therefore, descriptive statistics including mean and percent were used.
Moreover, to compare between provinces, districts and facilities, chi
square test was used. The formula of vaccine usage and vaccine wastage
rate is as bellow [4].
Vaccine usageðrateÞ¼Number of doses administered
Number of doses issued
 100
Vaccine wastage rate ¼ 100 – vaccine usage rate
Table 1. The catchment area of the selected facilities and codes in Hamadan, Kermanshah and Kordestan provinces and codes of each districts.
Province district Type of facility Name of Health Facility Health Facility code
1 Kordestan Divandarreh Health Post Qods1 331
2 Kordestan Divandarreh Health house 2 Ghaleh kohne 332
3 Kordestan Divandarreh Health house 1 Papaleh 333
4 Kordestan Sanandaj Health Post Asaveleh 312
5 Kordestan Sanandaj Health house 1 Barghru 311
6 Kordestan Sanandaj Health house 2 Avihang 313
7 Kordestan Baneh Health Post Health Facility No 4 321
8 Kordestan Baneh Health house 1 Aloot 322
9 Kordestan Baneh Health house 2 Bardeh rash 323
10 Kermanshah Eslamabad gharb Health house 2 Bagher abad 232
11 Kermanshah Eslamabad gharb Health house 1 Shiyan 231
12 Kermanshah Eslamabad gharb Health Post Health Facility No 2 233
13 Kermanshah Salas Babajani Health Post Nazeh abad 221
14 Kermanshah Salas Babajani Health house 1 Ziarat Tamrkhan 222
15 Kermanshah Salas Babajani Health house 2 Pookehabbas 223
16 Kermanshah Kermanshah Health house 1 Hojoom abad 211
17 Kermanshah Kermanshah Health house 2 Zameleh 212
18 Kermanshah Kermanshah Health Post Zeynabiyeh 213
19 Hamedan Hamedan Health house 1 Varkaneh 111
20 Hamedan Hamedan Health house 2 Khakoo 113
21 Hamedan Hamedan Health Post Chamran 112
22 Hamedan Toyserkan Health house 2 Hoosh 132
23 Hamedan Toyserkan Health house 1 Ghelghel 131
24 Hamedan Toyserkan Health Post Ghaem 133
25 Hamedan Bahar Health house 2 Mihmaleh Olaya 123
26 Hamedan Bahar Health house 1 Dahangerd 121
27 Hamedan Bahar Health Post Bahar 2 122
S.M. Zahraei et al. Heliyon 6 (2020) e040163. Results
3.1. MMR vaccine wastage
The six months' wastage rate for combined MMR 2-dose and 5-dose
opened vials for three studied provinces was 29% (CI 95%; 28%,30%),
Hamadan 18%(CI 95%; 17.9%,18.1%), Kermanshah 14%(CI 95%;
13.9%,14.1%), and Kordestan 52% (CI 95%; 51.9%,52.1%). MMR is used24%
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Figure 1. The Opened vial wastage rates of MMR and Pent
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in 2-dose and 5-dose vials. Figure 1 shows the opened vial wastage rates
in urban and rural facilities. and Table 2 shows the total wastage rate of
opened MMR 2-dose and 5-dose vials for three provinces and nine dis-
tricts included in the study for the period of six months. The more detail
about the MMR wastage rate by facilities is provided in Table 2.
Table 2 showed that the maximum wastage rate for total MMR (2-
dose and 5-dose vials) is 53% and the minimum rate is 0% for the fa-
cilities in the study the study facilities regardless of type and whether
they are in urban or rural areas. Table 2 showed that the wastage rate of
Pentavalent andMMRwas 24% and 13% respectively. It is also shows the%
17%
4%
25%
29%
20%
24%23%
15%
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MMR Penta
avalent in nine districts and based on each providence.
Table 2. Opened vial wastage rates of MMR and Pentavalent in comparison between rural and urban selected facilities.
Provinces Districts Facility codes Total wastage Pentavalent MMR
Pentavalent MMR Urban Rural Urban Rural
Kordestan Divandarreh 331 10% 22% 10% 22%
Kordestan Divandarreh 332 0% 71% 0% 71%
Kordestan Divandarreh 333 0% 18% 0% 18%
Divandarreh District 9% 24% 10% 13 22% 41%
Kordestan Sanandaj 311 7% 43% 7% 43%
Kordestan Sanandaj 313 0% 37% 0% 37%
Kordestan Sanandaj 312 15% 38% 15% 38%
Sanandaj District 13% 38% 15% 18 38% 40%
Kordestan Baneh 321 30% 53% 30% 53%
Kordestan Baneh 322 12% 43% 12% 43%
Kordestan Baneh 323 0% 45% 0% 45%
Baneh District 29% 53% 30% 6% 53% 44%
Kordestan Province 18% 40% 19% 2% 40% 41%
Kermanshah Eslamabad gharb 232 2% 5% 2% 5%
Kermanshah Eslamabad gharb 231 0% 7% 0% 7%
Kermanshah Eslamabad gharb 233 23% 24% 23% 24%
Eslamabad gharb District 19% 21% 23% 1% 24% 6%
Kermanshah Salas Babajani 221 13% 15% 13% 15%
Kermanshah Salas Babajani 222 3% 3% 3% 3%
Kermanshah Salas Babajani 223 0% 17% 0% 17%
Salas Babajani District 13% 15% 13% 2% 15% 4%
Kermanshah Kermanshah 211 20% 43% 20% 43%
Kermanshah Kermanshah 212 0% 50% 0% 50%
Kermanshah Kermanshah 213 23% 24% 23% 24%
Kermanshah District 23% 25% 23% 15% 24% 46%
Kermanshah Province 15% 17% 15% 3% 17% 13%
Hamedan Hamedan 111 0% 17% 6% 17%
Hamedan Hamedan 113 0% 25% 0% 25%
Hamedan Hamedan 112 4% 2% 5% 2%
Hamedan District 4% 4% 5% 4% 2% 19%
Hamedan Toyserkan 132 0% 44% 0% 44%
Hamedan Toyserkan 131 0% 21% 0% 21%
Hamedan Toyserkan 133 0% 24% 0% 24%
Toyserkan District 0% 25% 0% 0% 24% 28%
Hamedan Bahar 123 0% 50% 0% 50%
Hamedan Bahar 121 0% 21% 0% 21%
Hamedan Bahar 122 1% 26% 1% 26%
Bahar District 1% 29% 1% 0% 26% 44%
Hamedan Province 2% 20% 2% 1% 18% 34%
Total 13% 24% 14% 2% 25% 31%
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seen that only in two facilities pentavalent wastage is slightly more than
MMR wastage. In only two facilities (codes 111 and 112 and district 11)
the wastage rates of MMR are slightly less than wastage rates of
pentavalent.
The average of MMR 2-dose and 5-dose vials wastage rates by urban
and rural areas in this study was 26% (23% in urban and 29% in rural
areas). The MMR total wastage rate in rural facilities is higher than those
in urban areas (28.6% versus 21.2%).
The average of discarded unopened vials wastage rate in all facilities
for MMR total was 3.9% (3.2% for MR 2-dose vial and 10.2% for MMR 5-
dose vial). The total MMR (2-dose and 5-dose vials) wastage rate in
relation to the size of the target population showed that there is no clear
or systematic correlation between the target population and MMR total
wastage rates (Table 3). Table 3 showed the detail of all data collected for
MMR 2-dose and 5-dose vials in terms of wastage rate, areas (urban
versus rural), session size for each individual facility, separated by4
district and province. These results, only two facilities had only MMR 5-
dose vials whereas 17 facilities had only MMR 2-dose vial and the rest
(eight facilities) had both MMR 2-dose and 5-dose vials. However, the
MOH recommends to seize any opportunity for vaccination of children in
order to maintain a high coverage and little attention is made to vaccine
wastage rate.3.2. Pentavalent vaccine wastage
The six months' retrospective total wastage rate for combined
pentavalent single-dose and 10-dose vials was 17% (CI 95%;
16.5%,17.5%) for three provinces. This rate was 33%(CI 95%;
32.9%,33.1%) in Kordestan, 11%(CI 95%; 10.9%,11.1%) in Kermanshah
and 3%(CI 95%; 2.9%,3.1%) in Hamedan. The maximum wastage was in
Baneh 29% and Kermanshah 22% and the minimum in Salas e babajani
0%. In addition, the total average of pentavalent single-dose and 10-dose
vials wastage rate was 5% and varied 13% for urban and 3% for rural
Table 3. Summary of MMR wastage by facility (opened vial), vial size, number of sessions per month and based on urban versus rural areas.
Districts Facility
codes
Target
Population(children)
MMR wastage
rate (%)
Number of MMR Vaccination
sessions per month
Average number of MMR
Vaccination per sessions
Combination of 2-dose
and 5-dose vials*
Divandarreh 331 174 22 24 3.19 1.42
Divandarreh 332 6 50 24 0.03 0.42
Divandarreh 333 11 18 2 1.50 Only 2 dose vials
Sanandaj 311 7 43 4 1.04 Only 2 dose vials
Sanandaj 313 10 37 4 1.09 Only 2 dose vials
Sanandaj 312 57 23 4 5.42 0.76
Baneh 321 140 53 8 0.00 Only 5 dose vials
Baneh 322 6 33 4 0.36 Only 2 dose vials
Baneh 323 6 45 4 0.46 Only 2 dose vials
Eslamabad gharb 232 13 5 4 0.88 Only 2 dose vials
Eslamabad gharb 231 14 7 4 1.63 Only 2 dose vials
Eslamabad gharb 233 123 24 4 11 18.33
Salas Babajani 221 202 0 8 9.81 2.1
Salas Babajani 222 15 3 24 0.27 Only 2 dose vials
Salas Babajani 223 3 17 24 0.03 Only 2 dose vials
Kermanshah 211 4 33 24 0.06 Only 2 dose vials
Kermanshah 212 2 50 24 0.03 Only 2 dose vials
Kermanshah 213 90 24 8 0.0 Only 5 dose vials
Hamedan 111 6 17 24 .010 Only 2 dose vials
Hamedan 113 4 25 24 0.04 Only 2 dose vials
Hamedan 112 124 2 24 1.87 0.96
Toyserkan 132 5 44 24 0.06 Only 2 dose vials
Toyserkan 131 11 21 24 0.23 Only 2 dose vials
Toyserkan 133 82 15 12 2.57 5.39
Bahar 123 20 50 24 0.19 Only 2 dose vials
Bahar 121 5 21 24 0.08 Only 2 dose vials
Bahar 122 142 26 24 1.94 1.48
*Digits in last column indicate the ratio of the total number of doses in 5-dose vials to total number of doses in 2-dose vials. For instance, on the first row 1.42 means that
there were 230 MMR doses in 5-dose vials and 162 MMR doses in 2-dose vials.
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cilities for pentavalent total was 1.7% including 1.9% for single dose vial
and 0.4% for 10 dose vial.
Table 4 shows the detail of all data collected for pentavalent single-
dose and 10-dose vials in terms of wastage rate, areas (urban versus
rural), session size for each individual facility, combined for district and
province. As it can be seen from Table 4 that two facilities had both
pentavalent single-dose vials and 10-dose vials whereas 17 facilities had
only pentavalent single-dose vials and the rest (six facilities) had both
only pentavalent 10-dose vials.
Our results showed that the total pentavalent wastage (single-dose
and 10-dose vials) versus target population. It showed that rural health
facilities have had the least wastage rate because they were received just
single dose vials (Table 4). This pattern is not observed for MMR
(Table 3).
Reasons for discarding unopened vials in all three provinces were 44
doses VVM at stages 3 and 4 (22 vials) 2 doses (1 vials) lost and 2 (1 vials)
doses brooked for MMR 2-dose vial. Only 5 doses (1 Vial) lost in MMR 5-
dose vial and 10 doses (1 vial) of pentavalent 10-dose vial lost. In
pentavalent single dose vial also 3 doses (3 vials) discarded due to VVM
at stages 3 and 4, 1 dose (1 vial) due to lost and 2 doses (2 vials) brooked.
4. Discussion
The average wastage rate for MMR opened vials in this study esti-
mated to be 29%. The highest rate was observed in Kordestan (52%), and
was 14% in Kermanshah, while this rate estimated 18% for Hamadan in
2-dose and 5-dose vials. The Global Alliance for Vaccines and Immuni-
zations (GAVI), recommended that the maximumwastage rate of vaccine
should reduce to 25% at the first year and reduce it to 15% at the third5
year. Although, the maximum wastage allowance for single-dose or two-
dose vaccines is 5% [4]. Based on our results, the vaccine wastage in Iran
is over the GAVI guidelines. The mean wastage rates in facility-level of
Cambodia varied from 4% for single-dose of pentavalent vaccine to 60%
for 10-dose MCV [1]. Another study showed that the mean of vaccine
wastage rates in Nigeria varied from 18% to 35% based on vaccine type
[7]. The wastage rate for combined pentavalent single-dose and 10-dose
vials was 17% for three studied provinces including 33% in Kordestan,
11% in Kermanshah and 3% in Hamedan for single and 10-doses vials of
pentavalent. In Addition, the total average of pentavalent single-dose and
10-dose vials wastage rate was 5% and varied 13% for urban and 3% for
rural areas. The GAVI/WHO recommended wastage rate for pentavalent
is 5% [8] equal to our study. The average of discarded unopened vials
wastage rate in all facilities for pentavalent total was 1.7% including
1.9% for single dose vial and 0.4% for 10 dose vial. However, the average
of wastage rate in Iran for single dose andmulti dose of Pentavalent is 2%
and 10% respectively [21] but we did not find data about MMR wastage
rate. Another study in Nigeria showed that the monthly wastage rate for
all vaccines were estimated 25% [7]. The wastage vaccine rate was 35%
for MMR and 31 for DPT vaccines in Nigeria according to the facility
stock-based records wastage [7]. The wastage rate for measles and DPT
also estimated in Surat (India) 28% and 16% respectively [22].
This study shows that the average wastage rate of MMR was 28.6%
mainly due to very small target population. The MMR total wastage rate
in rural facilities is higher than those in urban areas. In rural areas of Iran,
only 2 dose MMR vials distributed in order to decrease wastage. How-
ever, the vaccine wastage is related to population size of districts. In the
other hand higher wastage rate in urban areas is due to a reflection of
more dosages of the trivalent vaccine than pentavalent vaccine being
administered. Wallace et al study showed that the wastage rates are
Table 4. Summary of pentavalent wastage by facility, vial size, number of sessions per month and based on urban versus rural areas– opened vial.
Districts Facility
codes
Target
Population
Penta wastage
rate (%)
Number of Penta Vaccination
sessions per month
Average number of Penta
Vaccination per sessions
Combination of single-dose
and 10-dose vials*
Divandarreh 331 174 10 24 3.85 5.68
Divandarreh 332 6 0 24 0.20 1.67
Divandarreh 333 11 0 24 0.28 Only single dose vials
Sanandaj 311 7 0 24 0.09 Only single dose vials
Sanandaj 313 10 0 24 0.17 Only single dose vials
Sanandaj 312 57 12 24 1.53 3.05
Baneh 321 140 30 24 0 Only 10 dose vials
Baneh 322 6 0 24 0.10 Only single dose vials
Baneh 323 6 0 24 0.12 Only single dose vials
Eslamabad gharb 232 13 2 24 0.35 Only single dose vials
Eslamabad gharb 231 14 0 24 0.29 Only single dose vials
Eslamabad gharb 233 123 2.3 24 2.80 73.33
Salas Babajani 221 202 0 24 5.38 8.42
Salas Babajani 222 15 0 24 0.27 Only single dose vials
Salas Babajani 223 3 0 24 0.06 Only single dose vials
Kermanshah 211 4 0 24 0.06 Only single dose vials
Kermanshah 212 2 0 24 0.02 Only single dose vials
Kermanshah 213 90 23 24 0 Only 10 dose vials
Hamedan 111 6 23 24 0.21 Only single dose vials
Hamedan 113 4 0 24 0.15 Only single dose vials
Hamedan 112 124 5 24 2.65 3.86
Toyserkan 132 5 0 24 0.15 Only single dose vials
Toyserkan 131 11 0 24 0.22 Only single dose vials
Toyserkan 133 82 3 24 1.49 21.58
Bahar 123 20 0 24 0.33 Only single dose vials
Bahar 121 5 0 24 0.10 Only single dose vials
Bahar 122 142 2 24 2.52 5.92
*Digits in this column indicate the ratio of the total number of doses in 10-dose vials to total number of doses in single-dose vials. For instance, on the first row 2.14
means that there were 420 pentavalent doses in 10-dose vials and 162 pentavalent doses in single-dose vials. The digits below one, means that number of doses in single-
dose vial was more than number of doses in 10-dose vials. These figures are one of the important parameters used in the WHO model.
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studies showed that similar results [22]. However, using single doses in
rural area caused lower vaccine wastage and as our results the vaccine
wastage is related to population size. The average number of target
population in rural health facilities was 15 (277 children in 18 health
facilities). Based on EPI schedule in Iran, every child receives 2 dose of
MMR at 12 and 18 months of age. This means that on average less than
three children were inoculated with MMR per month. Therefore, it would
be unavoidable to have MMR wastage rate above 25% by use of 2-dose
vials in rural areas. On the other hand, every urban health facility
covers 251 of target population (2,264 children in 9 health facilities).
Based on EPI schedule every urban health facility vaccinate 42 children
per month. Therefore, by use of 5-dose vial MMR vaccine, it would be
possible for them to have lower wastage rate if they managed their MMR
vaccination sessions. In addition, some urban health facilities used both 2
and 5-dose vials of MMR e.g. Health facilities 221 and 112. These two
facilities had the lowest wastage rate, 0% and 3%, respectively. The main
reason is the difference between content of MMR and pentavalent vac-
cines. The reconstituted MMR vials (no preservative) should be discarded
at the end of vaccination session while pentavalent multi-dose vials can
be used for 28 days after the opening of the vial in compliance with
multi-dose vial policy. Furthermore, distribution of single-dose vials of
pentavalent versus 2-dose vials of MMR vaccine has been influenced in
obtaining lower wastage rates of pentavalent in rural health facilities.
Based on the WHO about MDVP, the maximum recommended
wastage rates for multi-dose vials vaccines with preserved lyophilized
varied between 30 to 50% [8]. The estimated wastage of MMR and
pentavalent were lower than the MDVP. However, the wastage rate of
MMR should be reduced in Kermanshah and pentavalent in Kordestan to6
reached to WHO recommendations. The higher rate of vaccine wastage
could be related to higher rural and nomads' population. In addition, as
Karami et al study, the reporting of administrative vaccination data is
adequate at all levels of the healthcare provider centers [23].
Our results showed that only two facilities had only MMR 5-dose vials
whereas 17 facilities had only MMR 2-dose vial and the rest (eight fa-
cilities) had both MMR 2-dose and 5-dose vials. However, the MOH
recommends to seize any opportunity for vaccination of children in order
to maintain a high coverage and little attention is made to vaccine
wastage rates [2, 24]. Our results showed that the wastage rate was
higher in opened vials than closed vials and it is different among studied
facilities. Other showed same results and this difference due to some
factors including immersion of opened vials in water, uncertainty about
the sterility of prior withdrawals, thermal handling, and poor vaccine
administration practices [25, 26, 27].
The total MMR (2-dose and 5-dose vials) wastage rate in relation to
the size of the target population showed that there is no clear or sys-
tematic correlation between the target population and MMR total
wastage rates. It could be caused by the recommendations from the
higher levels to seize any opportunity to vaccinate children and giving
priority to vaccination coverage rather than to the wastage rate. More-
over, pentavalent vaccine in liquid form are used in single dose and 10-
dose vials. Our results showed that rural health facilities have had the
least wastage rate because they were received just single dose vials. This
pattern is not observed for MMR. However, it is understanding that usage
of single dose of pentavalent or 2 doses of MMR could yield the best
results and lower vaccine wastage. But the cost effectiveness analysis
should be considered. The cost of each dose of vaccine in MMR vials for
single, 2 and 5 doses is near 2, 1.5 and 0.6 US $. This costs for one dose of
S.M. Zahraei et al. Heliyon 6 (2020) e04016pentavalent in single and 10 doses in Iran is estimated 2 and 1.2 US $.
Based on a cost analysis, it is suggested that 2 doses vial of MMR and 10
doses of pentavalent are more effectiveness after considering the popu-
lation size of each districts. These activities could reduce the cost of
vaccinations [6, 7, 27, 28].
However, our finding is helpful as guide in implementation of future
improvement activities including contribute to development of policies,
strategies and standard operating procedures regarding vaccine pro-
curement, organization and implementation of services and vaccine
wastage control in MOH. Nevertheless, future studies suggested to esti-
mate the national vaccine wastages for all vaccines in routine immuni-
zation program in Iran.
5. Conclusion
The vaccine wastage rate in Iran are equivalent to the other countries
and lower than of maximum rate based on WHO multi-dose vial policy.
The wastage rates varied in different provinces, districts and health fa-
cilities. The MMR total wastage rate in rural is higher than those in urban
areas, but, the pentavalent total wastage rate was higher in urban area.
The relation between the wastage rates for both vaccines is related to
average number of vaccinations given during each session, number of
vaccination sessions per month and the size of the target population plus
some other factors looked at in this report.
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